JW Lifescience Corporation (234080) Fair Value & Analysis
Healthcare · KR · Market cap 177B KRW
Fair value as of: Jul 7, 2026
From 24 valuation models · updated today
Fair value updated Jul 7, 2026 — revised from 40,642 KRW to 33,878 KRW (−16.6%) since Jun 24, 2026. Share price +2.0% over the past month.
Price vs Fair Value (12 months)
12‑month range 10,730 KRW – 14,856 KRW · fair‑value band 23,902 KRW – 43,003 KRW · the 11,480 KRW price screens below the 33,878 KRW fair value. As of Jul 7, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
JW Lifescience Corporation (234080) currently trades at 11,480 KRW, while our model-based Fair Value estimate is 33,878 KRW — implying the stock looks roughly 195.1% undervalued today. We read business quality at 59/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, JW Lifescience Corporation generated revenue of 253B KRW at a net margin of 11.6%. Revenue declined 7.4% year over year. It earns a return on equity of 14.0%. Net debt stands at 40.6B KRW. Fundamentals as of Jul 7, 2026
Our scenario range runs from 23,902 KRW (bear case) to 43,003 KRW (bull case); at 11,480 KRW, the current price sits below that range. The share trades about 23% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside — at 195%, 234080 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.
About the company
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
JW Lifescience Corporation reported revenue of 258B KRW in FY2025 versus 170B KRW in FY2021, a compound +11.0%/yr. Reported net income was 28.6B KRW in FY2025, compounding +22.0%/yr from FY2021.
Is 234080 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,272 | ₹720.15 | -43% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is JW Lifescience Corporation (234080) undervalued?
What is the fair value of 234080?
What is the quality score of 234080?
What is the revenue of JW Lifescience Corporation (234080)?
What is the net profit margin of 234080?
Does JW Lifescience Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.